New Long-Acting Insulin Drug Enters Market With FDA Approval

Physicians have another medication at their disposal for treating diabetes after the Food and Drug Administration Thursday approved a new long-acting insulin product derived from the established drug Lantus.

Mylan’s Semglee is the second insulin product approved based on information from Sanofi’s Lantus, a long-acting manufactured insulin given the green light in 2000, according to an FDA spokesman. The first such “follow-on” was Ely Lilly’s Basaglar which was approved in 2015.

The drug is available to treat Type I and Type II diabetes.

The approval happened against a backdrop of controversy regarding the cost of insulin and other treatments related ...